SCHEMBL14956008

SCHEMBL14956008

CC(=O)N1CCN(c2ccc(Nc3nc(NC4CC4)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 17/20 0.65
▸ ALK Q9UM73 3/20 0.54
▸ RET P07949 2/20 0.54
▸ ROS1 P08922 2/20 0.54
▸ FLT3 P36888 2/20 0.54
▸ EML4 Q9HC35 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14956011 0.92 SYK (0.67) SYK
SCHEMBL16541266 0.88 EML4 (0.70) SYKALKRETROS1FLT3
SCHEMBL10129237 0.84 RET (0.55) SYKALKRETROS1FLT3
SCHEMBL17690593 0.82 SYK (0.50) SYKALKRETROS1FLT3
SCHEMBL17690654 0.79 EML4 (0.53) SYKALKRETROS1FLT3
SCHEMBL735847 0.78 SYK (1.00) SYK
SCHEMBL16195530 0.78 BTK (0.43) SYKALKRETROS1FLT3
SCHEMBL10129427 0.77 EML4 (0.59) SYKALKRETROS1FLT3
SCHEMBL18283441 0.77 SYK (0.51) SYKALKRETROS1FLT3
SCHEMBL18283443 0.77 SYK (0.51) SYKALKRETROS1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359308-B2 Pyrazine kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 — — US disclosed
US-9359308-B2 Pyrazine kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 — — US disclosed
US-9359308-B2 Pyrazine kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 — — US disclosed
US-8877760-B2 Substituted pyrazine-2-carboxamide kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2014-11-04 — — US disclosed
US-8877760-B2 Substituted pyrazine-2-carboxamide kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2014-11-04 — — US disclosed
US-8877760-B2 Substituted pyrazine-2-carboxamide kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2014-11-04 — — US disclosed
US-20140309209-A1 Pyrazine Kinase Inhibitors ALEXION PHARMACEUTICALS, INC. 2014-10-16 — — US disclosed
US-20140309209-A1 Pyrazine Kinase Inhibitors ALEXION PHARMACEUTICALS, INC. 2014-10-16 — — US disclosed
US-20140309209-A1 Pyrazine Kinase Inhibitors ALEXION PHARMACEUTICALS, INC. 2014-10-16 — — US disclosed
EP-2782579-A1 PYRAZINE KINASE INHIBITORS Portola Pharmaceuticals, Inc. (US) 2014-10-01 — — EP disclosed
WO-2013078466-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 — — WO disclosed
US-20130131040-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed
US-20130131040-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed
US-20130131040-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131040-A1 PYRAZINE KINASE INHIBITORS SYK, ZAP70, LCK SYK 1/4885ALK 281/4885RET 335/4885
US-20140309209-A1 Pyrazine Kinase Inhibitors SYK, ZAP70, LCK SYK 1/4885ALK 281/4885RET 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback